Quest Diagnostics Q3 2026 Earnings: The $3.1B Quarter Where Volume Did All the Work

Quest Diagnostics grew revenue 10% in the third quarter on 14.5% more requisitions — while collecting 4.2% less per requisition. That is the whole quarter in one sentence: the lab-services leader is running more tests for more people than ever, and the mix of those tests keeps getting cheaper. Reported diluted EPS still jumped 28.7% to $2.78 and management raised full-year guidance on both lines, so the market will cheer the headline. But the ledger shows a subtler story — margin expansion built on lapped one-offs and SG&A leverage, a balance sheet where partners now own $318 million of equity that was $36 million nine months ago, and growth increasingly rented from hospital joint ventures rather than owned outright.

The Headline Numbers​

Quest's fiscal year is the calendar year and no Q3 10-Q has been filed yet, so every figure below comes from the Form 8-K and the earnings release attached as its Exhibit 99.1, which carries full unaudited face statements. One auditor's note before the table: the release's growth percentages are computed on unrounded inputs, so a few run a tenth or two hotter than the printed millions divide to (net income +27.6% vs. +27.3%, operating income +24.2% vs. +24.1%). The tables below use the filed figures and the growth rates they compute to.

Net income here and everywhere below is attributable to Quest Diagnostics — the $326 million of consolidated Q3 net income less the $14 million belonging to noncontrolling-interest partners, deducted the way the filing deducts it. The standout row is operating income: up 24% on 10% revenue growth, a 1.8-point margin expansion. What moved it is the subject of the margin section, and the honest answer is less heroic than the percentage — about two-fifths of the expansion is last year's charges not repeating.

The GAAP-to-non-GAAP bridge shows where the $0.22 gap between reported and adjusted EPS lives:

Amortization of acquired intangibles is two-thirds of the adjustment, every quarter, as it is for every serial acquirer. The $149 million full-year amortization estimate in the guidance footnotes tells you the M&A machine is still the model.

Revenue Deep Dive​

Quest reports one segment that matters. Diagnostic Information Services (DIS) was $3,035 million of the $3,097 million quarter, up 10.2%; the DS risk-assessment and health-IT businesses contributed the remaining $62 million and have shrunk three years running ($276M → $258M → $250M). Within DIS, the release gives the volume-price split that defines the quarter:

Volume up fourteen and a half, price down four. The release itself does not decompose the Q3 mix shift, but the first-half 10-Q tells us exactly what this signature means: about 8 points of H1 volume growth came from two new relationships — the Corewell Health joint venture in Michigan and expanded testing at Fresenius dialysis clinics — both weighted toward routine tests that carry below-average revenue per requisition. Strip those two out and H1 revenue per requisition rose about 2.5% on more tests per requisition and favorable mix. Q3 shows the same fingerprint at higher volume, which means the partnership engine accelerated into the quarter.

CEO Jim Davis's quote is worth reading against that ledger line: "continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI," plus "robust organic revenue growth" proving the company is "fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness." That is a robust-demand signal across all three customer channels — physician labs were 71% of 2025 revenue, hospital 18% — with a prevention-and-wellness market-expansion kicker. The channel mix confirms the hospital leg is structural, not cyclical: hospital outreach and Co-Lab Solutions deals (the new Northeastern health-system asset acquisition announced this quarter, the Corewell JV lab opening in 2027) convert competitors' lab volume into Quest requisitions at routine-test prices. More requisitions, thinner per unit, consolidated onto Quest's fixed-cost network. That is the strategy working as designed — but it means headline revenue growth will keep understating volume growth for as long as the partnership book keeps expanding.

What the release does not say is also a finding: there is no pricing language anywhere — no "pricing momentum," no contract-price commentary. In a quarter where revenue per requisition fell 4.2%, management talked about volume, channels and productivity. Price is not a lever here; throughput is.

The Margin Story​

Gross margin was flat year over year — cost of services grew 10.1%, a touch faster than revenue — so the entire 1.8 points of operating expansion came below gross profit. The walk is mechanical and fully attributable:

• SG&A leverage, ~0.9pp. Selling, general and administrative expense grew only 4.4% ($523M on $3,097M) against 10% revenue growth, taking the ratio from 17.8% to 16.9%. This is the automation-and-AI productivity the CEO cited, plus the operating leverage of running 14.5% more requisitions through the same billing and administrative infrastructure.
• Lapped one-offs, ~0.7pp. Other operating expense fell from $23M to $3M. Last year's quarter held a $15 million legal-matters charge and a $5 million impairment on a business exit — $20 million that did not repeat accounts for 0.7 points of the 1.8-point expansion all by itself.
• Amortization drift, ~0.2pp. The amortization line keeps shrinking relative to a growing revenue base ($37M vs. $39M absolute).

None of this is low quality — SG&A leverage on volume growth is exactly what a fixed-cost lab network should produce — but it reframes the 24% operating-income growth. The run-rate expansion from operations is roughly one point, not two; the rest is the comparison flattering the quarter. Below operating income, the picture is clean: net interest ticked down to $61M, the effective tax rate held near 24%, and equity-method earnings added $9M.

The One Big Question: Who Owns the Growth?​

The most consequential number in the Q3 balance sheet is not revenue or margin. It is noncontrolling interests: $318 million, up from $36 million at year-end 2025. In nine months, outside partners' claim on Quest's consolidated equity grew nearly ninefold, and the Q3 income statement already deducts their $14 million share before arriving at the $312 million attributable to Quest shareholders.

The Q2 10-Q names the cause. In January 2026 Quest closed its joint venture with Corewell Health: Quest paid $38 million in cash and granted Corewell a 49% noncontrolling interest valued at $253 million in the new Michigan lab entity, which Quest consolidates at 51%. The equity statement records $263 million of first-half contributions from NCI partners, and the balance kept climbing to $318 million by September. A second Co-Lab deal — the Northeastern health-system outreach assets announced this quarter — points the same direction.

This deserves a clear-eyed reading in both directions. The bull case is that Quest is consolidating hospital outreach volume without paying acquisition multiples: Corewell contributed its lab business, Quest contributed $38 million and its operating platform, and 100% of the entity's revenue now flows through Quest's DIS line while only 51% of its economics belong to shareholders. The bear case is dilution by structure — every future Co-Lab JV done this way widens the wedge between consolidated growth and per-share growth, and the 49% partners get paid first. Watch the ratio: in Q3 the NCI deduction was still just $14 million on $326 million of consolidated net income (4.3%). If the JV book keeps growing, that share rises, and quarters like this one — 10% consolidated revenue growth — will translate into something less for Quest shareholders. The ledger makes the wedge visible every quarter; make it the first thing you check.

Tracking a $17B Company in Plain Text​

A diagnostics company is an ideal plain-text accounting subject: one dominant segment, no inventory complexity, and a balance sheet where every acquisition leaves a permanent goodwill fossil. Modeling Quest in Beancount forces each of those fossils to reconcile — this is the company. Our conventions for how we model every company put the redeemable NCI in mezzanine equity exactly where the filing puts it, and deduct the partners' earnings share the way the income statement does.

Here is the quarter, as the ledger records it (income negative, expenses positive — Beancount sign conventions):

; FY2026Q3 Income Statement — three months ended September 30, 2026
; Check: −3,097 + 2,055 + 523 + 37 + 3 + 61 + 2 + 99 − 9 + 14 + 312 = 0 ✓
 
2026-09-30 * "Quest Diagnostics Incorporated" "FY2026Q3 Income Statement"
  Income:Revenue                         -3097 MUSD  ; net revenues (Diagnostic Information Services 3,035; all other 62)
  Expenses:CostOfRevenue                  2055 MUSD  ; cost of services
  Expenses:SellingGeneralAdministrative     523 MUSD  ; selling, general and administrative
  Expenses:AmortizationOfAcquiredIntangibles  37 MUSD  ; amortization of intangible assets
  Expenses:OtherNet                            3 MUSD  ; other operating expense, net
  Expenses:Interest                           61 MUSD  ; interest expense, net
  Expenses:OtherNet                            2 MUSD  ; other expense, net
  Expenses:IncomeTax                          99 MUSD  ; income tax expense
  Income:OtherNet                             -9 MUSD  ; equity in earnings of equity method investees, net of taxes
  Expenses:OtherNet                           14 MUSD  ; net income attributable to noncontrolling interests, deducted as the filing does
  Equity:Adjustments                         312 MUSD  ; net income attributable to Quest Diagnostics offset (RE set by balance assertion)

The one balance-sheet number that tells the narrative is goodwill: $9,112 million — 53% of total assets. LifeLabs, the 2024 health-system deals, Haystack Oncology: every acquisition sits in that line, net of nothing, and it grew another $167 million in nine months. Against it, treasury stock of $5,294 million records the other capital-allocation habit — Quest has bought back roughly a third of its issued shares. The company simultaneously acquires growth and retires its own equity; both strategies are visible in two lines of the ledger.

The Multi-Year Arc​

(FY2022–FY2023 from the comparative columns of the FY2024 10-K; segment and goodwill comparatives as disclosed.)

The arc is a comedown and a rebuild. FY2022 still carried COVID-testing revenue; FY2023 washed it out (revenue −6.4%, net income −9.7%) and reset the base. Since then Quest has compounded revenue 9.2% annually for two years — but FY2025's own MD&A admits the mix: organic growth was 5.3% while acquisitions contributed 6.7% of DIS revenue. The M&A engine (LifeLabs closed August 2024, plus Allina, OhioHealth, University Hospitals outreach deals) rebuilt the top line faster than the core could. Q3 2026 is the first quarter where the mix flips encouragingly: 14.4% organic volume growth means the core is finally outrunning the deal book — even if the Corewell and Fresenius partnerships blur the line between "organic" and "partnered" volume.

Full-year guidance raised the bar accordingly: revenue $12.065–12.105 billion (+9.3–9.7%), reported diluted EPS $10.21–10.31, adjusted $11.25–11.35, operating cash flow about $1.90 billion against $550 million of capex. Nine-month operating cash flow of $1,486 million less $418 million of capex already puts free cash flow above $1 billion with one quarter of the year still to go.

The Verdict: Bull vs. Bear​

Bull Case

• Volume breadth is real and accelerating. Organic requisition growth of 14.4% — with strength called out across physician, hospital and consumer channels — is the strongest demand print in the ledger's history, and the raised revenue guide ($12.065–12.105B) says management expects it to hold.
• Operating leverage is working. SG&A grew 4.4% against 10% revenue growth; every incremental requisition carries less overhead, and automation/AI productivity is a cited, ongoing program (Invigorate), not a one-time cut.
• New demand vectors are opening. An Apple Health app channel putting 50-biomarker panels in front of iPhone users, plus the FDA-cleared pTau217 Alzheimer's blood test extending the AD-Detect menu, give the consumer and esoteric franchises (38% of revenue) identifiable growth drivers into 2027.
• Cash conversion funds both habits. Nine-month free cash flow above $1 billion covers the $279 million of dividends, $252 million of buybacks and the tuck-in acquisition pace simultaneously — the balance sheet funds growth and shareholder returns without stretching (net debt roughly $4.8B against a $17.2B balance sheet).
• The JV structure buys volume cheap. The Corewell deal cost $38 million of cash for control of a consolidated lab business; if Co-Lab Solutions replicates across health systems, Quest acquires outreach volume at fractions of M&A multiples.

Bear Case

• Every unit of growth is cheaper than the last. Revenue per requisition fell 4.2% — the partnerships driving volume are routine-test heavy, and nothing in the release suggests pricing power anywhere in the book. If mix keeps diluting, double-digit volume growth produces single-digit revenue growth indefinitely.
• The margin beat is half comparison. Roughly 0.7 of the 1.8 points of operating expansion is lapping Q3 2025's $15 million legal charge and $5 million impairment; the run-rate gain is about one point of SG&A leverage, and gross margin actually ticked down.
• Receivables are outrunning revenue. Accounts receivable rose 21.6% since year-end ($1,408M → $1,712M) against 10% revenue growth — the billing-and-reimbursement complexity the 10-K warns about is visibly tying up working capital.
• Goodwill is the balance sheet. $9.1 billion — 53% of assets — must earn its carry through volume that increasingly belongs 49% to partners; a hospital JV that underperforms impairs both the asset and the growth story.
• Two open items carry no numbers yet. The release's risk paragraph references "the incident described in the Current Report on Form 8-K filed on October 22, 2026," with no separate incident filing visible on EDGAR — and the $282 million of new NCI equity will take an increasing share of future earnings before Quest shareholders see a dollar.

Our Take

Buy the volume, discount the multiple. Quest just printed the strongest organic demand in its recent history, converted it at expanding operating margins, and raised guidance — that is a genuinely good quarter, and the hospital-partnership flywheel plus consumer/Alzheimer's optionality give it legs. But 10% revenue growth built on 14.5% volume growth at −4.2% unit economics, with half the margin expansion coming from lapped charges and a growing slice of earnings owed to JV partners, is worth less per dollar than the headline suggests. The Corewell template will either become the industry's best capital-light growth engine or a slow dilution of the per-share story — and the NCI line, now $318 million, is where that verdict will arrive first. We are constructive on the business and would want the JV economics disclosed quarterly before paying up for it.